Title:
BICYCLIC PEPTIDE LIGAND OF MT1-MMP AND CONJUGATE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/088236
Kind Code:
A1
Abstract:
Provided are a peptide having high affinity to membrane-type matrix metalloproteinase 1 (MT1-MMP), a drug conjugate, stereoisomer, pharmaceutically acceptable salt, solvate, co-crystal or deuterated product thereof, or a pharmaceutical composition containing same, and a use of the peptide ligand and drug conjugates in the prevention and treatment of diseases or disorders in which MT1-MMP is overexpressed in diseased tissue of individuals suffering from tumors.
Inventors:
LI YAO (CN)
CHEN LEI (CN)
HUANG HAITAO (CN)
WANG HAODONG (CN)
TANG PINGMING (CN)
YU YAN (CN)
ZHANG CHEN (CN)
YAN PANGKE (CN)
CHEN LEI (CN)
HUANG HAITAO (CN)
WANG HAODONG (CN)
TANG PINGMING (CN)
YU YAN (CN)
ZHANG CHEN (CN)
YAN PANGKE (CN)
Application Number:
PCT/CN2022/131909
Publication Date:
May 25, 2023
Filing Date:
November 15, 2022
Export Citation:
Assignee:
HAISCO PHARMACEUTICAL GROUP CO LTD (CN)
International Classes:
C07K7/08; A61K47/64; A61K51/04; A61K51/08; A61P35/00
Foreign References:
| CN107148425A | 2017-09-08 | |||
| CN113518648A | 2021-10-19 | |||
| CN113507962A | 2021-10-15 | |||
| CN113474047A | 2021-10-01 | |||
| CN109414510A | 2019-03-01 | |||
| CN110506049A | 2019-11-26 |
Other References:
EDER, M ET AL.: "Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors", CANCER RESEARCH, vol. 79, no. 4, 15 February 2019 (2019-02-15), pages 841 - 852, XP055669350, DOI: 10.1158/0008-5472.CAN-18-0238
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: